Outcomes after radio(chemo)therapy for non-metastatic bile duct cancer

Louisa Bolm, Lukas Kaesmann, Tobias Bartscht, Steven E. Schild, Dirk Rades

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Background/Aim: The role of radio(chemo) therapy for non-metastatic bile duct cancer is not well defined. This study provides additional data for this rare situation. Patients and Methods: Data of eight patients receiving radio(chemo)therapy for non-metastatic bile duct cancer were retrospectively analyzed regarding local control, metastasesfree survival and overall survival. In addition to the entire cohort, five tumor-or treatment-related factors were investigated: Tumor stage, histologic grading, point in time of radio(chemo)therapy, upfront surgery and concurrent chemotherapy. Results: Median overall survival was 37 months. Overall survival rates at 3 and 5 years were 56% and 38%, respectively. Lower histologic grading was significantly associated with better overall survival (p=0.042). Metastasesfree survival rates at 3 and 5 years were 38% and 19%, while local control rates were 43% and 21%, respectively. Concurrent radiochemotherapy (vs. radiotherapy alone) resulted in significantly improved local control (p=0.014). Conclusion: Radiochemotherapy can achieve promising results in selected patients with non-metastatic bile duct cancer.

Original languageEnglish (US)
Pages (from-to)117-120
Number of pages4
JournalIn Vivo
Volume31
Issue number1
DOIs
StatePublished - 2017

Keywords

  • Concurrent Radiochemotherapy
  • Local Control
  • Metastases-Free Survival
  • Non-Metastatic Bile Duct Cancer
  • Overall Survival.
  • Radiotherapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Fingerprint Dive into the research topics of 'Outcomes after radio(chemo)therapy for non-metastatic bile duct cancer'. Together they form a unique fingerprint.

  • Cite this

    Bolm, L., Kaesmann, L., Bartscht, T., Schild, S. E., & Rades, D. (2017). Outcomes after radio(chemo)therapy for non-metastatic bile duct cancer. In Vivo, 31(1), 117-120. https://doi.org/10.21873/invivo.11033